GlassScriptPhysician profile
Michael S Schorr
NPI 1508922089
$4,612.90
in general payments reported to CMS, 2019-2025
35 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $1,251 · 2021: $848 · 2022: $698 · 2023: $367 · 2024: $218 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $668.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $654.28 | 2019-2024 | Airsupra |
| Glaxosmithkline, LLC. | $351.16 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.67 | 2019-2024 | Jardiance |
| Abbvie INC. | $247.61 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Allergan, INC. | $234.97 | 2020 | |
| Lilly USA, LLC | $198.73 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $185.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $183.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $151.07 | 2019-2021 | |
| Novo Nordisk INC | $139.86 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $138.01 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $136.39 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $115.66 | 2019-2020 | |
| Amgen INC. | $103.87 | 2020-2025 | Repatha, Otezla, Otezla |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $96.21 | 2023-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $86.92 | 2019-2020 | |
| Baxter Healthcare | $72.70 | 2023 | Hillrom - Life 2000 Ventilation System |
| Eisai INC. | $72.49 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $51.20 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $43.10 | 2021-2025 | |
| Biodelivery Sciences International, INC. | $39.15 | 2019 | |
| Phathom Pharmaceuticals, INC. | $34.64 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.80 | 2019 | |
| Nestle Healthcare Nutrition INC. | $33.33 | 2021 | |
| Corcept Therapeutics | $33.26 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $30.61 | 2022 | |
| Dexcom, INC. | $27.29 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $24.68 | 2021 | |
| Indivior INC. | $23.74 | 2021 | |
| Smith+Nephew, INC. | $19.74 | 2020 | |
| Akebia Therapeutics INC | $15.41 | 2019 | |
| Scilex Pharmaceuticals INC. | $15.03 | 2022 | |
| Phadia US INC. | $13.10 | 2019 | |
| Mannkind Corporation | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schorr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.